Jen-Chieh (Jay) Chuang

Step away from the slide decks and join informal, peer-led discussion groups. Share experiences, debate novel methodologies, and benchmark strategies with your peers in an intimate, high-value networking environment.

• Assessing how biomarker-driven patient stratification strategies can reduce heterogeneity and improve therapeutic signal detection in clinical studies
• Exploring emerging endpoint approaches that better capture disease progression and treatment impact, enabling stronger efficacy assessment
• Discussing how sponsors can balance scientific rigor, operational feasibility and regulatory expectations to optimize future trial design

• Generating deeper insights into disease progression and treatment response through integrated biomarker approaches to better characterize patient populations, enabling more informed development strategies and improving trial precision
• Leveraging exploratory biomarker readouts to improve decision-making, reducing development risk and accelerating program progression
• Aligning biomarker strategies with regulatory and clinical endpoints to strengthen translational confidence, improving development efficiency and supporting future adoption of non-invasive approaches